Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2019

The Pharma Closeout tracks 180 deals, $330.4B in disclosed deal value, 29 with a post-close Outcome Score for the year 2019.

Median Critic Score: 75  ·  Median Outcome Score: 62

Best outcome: AstraZeneca PLC / Daiichi Sankyo Company, Limited (100)  ·  Weakest outcome: Sanofi SA / Synthorx Inc. (15)

All 180 deals

• AstraZeneca PLC / Daiichi Sankyo Company, Limited — 2019 · $6.9B · Worked — the deal delivered on its rationale.
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2019 · $3.3B · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / Loxo Oncology, Inc. — 2019 · $8.0B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Peloton Therapeutics Inc. — 2019 · $2.2B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. — 2019 · $950M · Worked — the deal delivered on its rationale.
• Exact Sciences Corporation / Genomic Health, Inc. — 2019 · $2.8B · Worked — the deal delivered on its rationale.
• Stryker Corporation / Wright Medical Group N.V. — 2019 · $5.4B · Worked — the deal delivered on its rationale.
• Merck KGaA / Versum Materials — 2019 · $5.8B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Celgene Corporation — 2019 · $74.0B · Worked — the deal delivered on its rationale.
• Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. — 2019 · $1.0B · Worked — the deal delivered on its rationale.
• Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) — 2019 · $21.4B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Array BioPharma Inc. — 2019 · $11.4B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Nurix Therapeutics Inc. — 2019 · $2.3B · Largely worked — most objectives met.
• Amgen Inc. / Otezla (from Celgene/BMS) — 2019 · $13.4B · Largely worked — most objectives met.
• Roche Holding AG / Sarepta Therapeutics Inc. — 2019 · $1.7B · Largely worked — most objectives met.
• AbbVie Inc. / Allergan plc — 2019 · $63.0B · Largely worked — most objectives met.
• Bayer AG / Arvinas, Inc. — 2019 · $1.0B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / ArQule Inc. — 2019 · $2.7B · Mixed — partial payoff, real shortfalls.
• Neurocrine Biosciences Inc. / Voyager Therapeutics Inc. — 2019 · $1.9B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Seagen Inc. — 2019 · $4.2B · Mixed — partial payoff, real shortfalls.
• Mylan N.V. / Upjohn Inc. (Pfizer) — 2019 · $12.0B · Underwhelmed — fell short of the thesis.
• Novartis AG / Takeda Pharmaceutical Company Ltd. — 2019 · $5.3B · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
• GSK plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
• Roche Holding AG / Spark Therapeutics Inc. — 2019 · $4.3B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Goldfinch Bio Inc. — 2019 · $240M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Galapagos NV — 2019 · $5.1B · Did not work — the deal failed to deliver.
• Astellas Pharma Inc. / Audentes Therapeutics — 2019 · $3.0B · Did not work — the deal failed to deliver.
• Sanofi SA / Synthorx Inc. — 2019 · $2.5B · Did not work — the deal failed to deliver.
• BioGenetics Co Ltd / ASLAN Pharmaceuticals — 2019
• Bristol-Myers Squibb Company / FameWave Ltd. — 2019
• Selecta Biosciences, Inc. / Asklepios BioPharmaceutical, Inc. — 2019
• Bayer AG / Foundation Medicine, Inc. — 2019
• Sarepta Therapeutics Inc. / StrideBio, Inc — 2019
• Astellas Pharma Inc. / Potenza Therapeutics, Inc. — 2019 · $405M
• 3M Company / M*Modal — 2019 · $1.0B
• Taisho Pharmaceutical Co., Ltd. / Moberg Pharma AB — 2019
• Ellipses Pharma Limited / NewLink Genetics Corporation — 2019
• Biogen Inc. / Nightstar Therapeutics — 2019 · $800M
• CStone Pharmaceuticals / Numab Therapeutics AG — 2019
• Castle Creek Pharmaceuticals / Fibrocell Science, Inc. — 2019
• GeoVax Labs, Inc. / Enesi Pharma — 2019
• Bayer / Moberg Pharma — 2019
• H. Lundbeck A/S / Alder BioPharmaceuticals, Inc. — 2019 · $1.9B
• Bristol-Myers Squibb Company / Anokion SA / Kanyos Bio Inc. — 2019 · $1.3B
• AbbVie / Voyager Therapeutics Inc. — 2019
• Torii Pharmaceutical, Co. / BioCryst Pharmaceuticals, Inc. — 2019
• Thermo Fisher Scientific Inc. / Brammer Bio — 2019 · $1.7B
• Roche Holding AG / Sosei Group Corporation (Sosei Heptares) — 2019 · $1.0B
• Alexion Pharmaceuticals, Inc. / Zealand Pharma A/S — 2019
• Pfizer Inc. / Akcea Therapeutics / Ionis Pharmaceuticals (AKCEA-ANGPTL3-LRx license) — 2019 · $1.3B
• Eli Lilly and Company / AC Immune SA — 2019 · $1.9B
• pH Pharma Co. Ltd. / Immunome Inc. — 2019
• Everest Medicines II Limited / Immunomedics Inc. — 2019
• Boehringer Ingelheim GmbH / AMAL Therapeutics SA — 2019 · $366M
• Otonomy, Inc. / Applied Genetic Technologies Corporation — 2019
• Hope Medicine Inc. / Bayer AG — 2019
• Ultragenyx Pharmaceutical Inc. / GeneTx Biotherapeutics LLC — 2019
• SiSaf Ltd / Avellino Labs USA, Inc. — 2019
• Eli Lilly and Company / AurKa Pharma Inc. — 2019 · $575M
• Phio Pharmaceuticals Corp. / Glycostem Therapeutics BV — 2019
• Biofrontera Inc., USA / Cutanea Life Sciences, Inc., USA — 2019
• Servier / OSE Immunotherapeutics — 2019
• ImmunoForge, Co. Ltd. / PhaseBio Pharmaceuticals, Inc. — 2019
• Merck & Co. Inc. / 4D pharma plc — 2019
• Genmab A/S / CureVac AG — 2019
• Novartis AG / Xiidra (lifitegrast) from Takeda — 2019 · $5.3B
• 3SBio Inc. / Verseau Therapeutics, Inc. — 2019
• NovoCodex Biopharmaceuticals Ltd. / Ambrx — 2019
• Zai Lab Ltd. / Deciphera Pharmaceuticals, Inc. — 2019
• Innovent Biologics, Inc. / Chipscreen Biosciences — 2019
• Acerta Pharma / Forty Seven Inc. — 2019
• Chongqing Jingdong Junzhuo Pharmaceutical Co., Ltd. / Athenex, Inc. — 2019
• SymBio Pharmaceuticals, Ltd / Chimerix — 2019
• Ipsen S.A. / Clementia Pharmaceuticals Inc. — 2019 · $1.3B
• Bristol-Myers Squibb Company / WindMIL Therapeutics — 2019
• BlueRock Therapeutics LP / Editas Medicine, Inc. — 2019
• Simcere Pharmaceutical Group / JW Pharmaceutical — 2019
• Vyera Pharmaceuticals, LLC / CytoDyn Inc. — 2019 · $88M
• Editas Medicine, Inc. / Asklepios BioPharmaceutical, Inc. — 2019
• Astellas Pharma Inc. / NapaJen Pharma, Inc. — 2019
• Kaken Pharmaceutical Co., Ltd. / Corbus Pharmaceuticals Holdings, Inc. — 2019
• Medison Pharma Ltd. / Origin Biosciences — 2019
• Vertex Pharmaceuticals Incorporated / Exonics Therapeutics — 2019 · $1.0B
• Knight Therapeutics Inc. / Biotoscana Investments S.A. — 2019
• ADC Therapeutics / Adagene Inc. — 2019
• Novartis AG / IFM Tre, Inc. — 2019 · $1.6B
• Adaptimmune Therapeutics plc / Alpine Immune Sciences, Inc. — 2019
• Genmab / BliNK Biomedical — 2019
• HanX Biopharmaceuticals, Inc. / Onconova Therapeutics, Inc. — 2019
• Ascentage Pharma / Shanghai Junshi Biosciences Co., Ltd. — 2019
• UCB S.A. / Ra Pharmaceuticals, Inc. — 2019 · $2.1B
• Chong Kun Dang Pharmaceutical Corporation / OSE Immunotherapeutics — 2019
• Betta Pharmaceuticals Co Ltd / Merus N.V. — 2019
• Johnson & Johnson Innovation LLC / AdoRx Therapeutics — 2019
• Royalty Pharma / Biohaven Pharmaceutical Holding Co. Ltd. (rimegepant funding) — 2019 · $200M
• Johnson & Johnson / Auris Health, Inc. — 2019 · $5.8B
• Innovent Biologics, Inc. / Shenogen Pharma Group Ltd. — 2019
• Newsoara Biopharma / TaiwanJ Pharmaceuticals — 2019
• Janssen Pharmaceuticals, Inc. / Locus Biosciences Inc. — 2019
• Baergic Bio, Inc. / AstraZeneca — 2019
• Biolab Sanus Pharmaceutical / Quantum Genomics — 2019
• Roche Holding AG / Adaptive Biotechnologies Corp. — 2019 · $2.3B
• Takeda Pharmaceutical Company Limited / Prometheus Biosciences Inc. — 2019
• Global Blood Therapeutics Inc. / Syros Pharmaceuticals, Inc. — 2019
• Huons Co., Ltd / LIPAC Oncology LLC — 2019
• CRISPR Therapeutics / KSQ Therapeutics — 2019
• Cerecor Inc. / Aevi Genomic Medicine — 2019 · $16M
• Knight Therapeutics Inc. / Puma Biotechnology, Inc. — 2019 · $7M
• CSL Behring / aTyr Pharma, Inc. — 2019
• Decibel Therapeutics / Cocoon Biotech — 2019
• Merck & Co. Inc. / Immune Design Corp. — 2019 · $300M
• Serum AMR / Aridis Pharmaceuticals, Inc. — 2019
• Mallinckrodt plc / Silence Therapeutics plc — 2019
• Ascletis Pharma Inc. / Suzhou Alphamab Co., Ltd. — 2019
• Autolus Therapeutics plc / Noile-Immune Biotech, Inc. — 2019
• Accord Healthcare / Foresee Pharmaceuticals — 2019 · $86M
• Boston Scientific Corporation / Vertiflex, Inc. — 2019 · $465M
• BiomX Ltd. / JSR Corporation — 2019
• Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal) — 2019 · $3.0B
• CytoSen Therapeutics / B-MoGen Biotechnologies, Inc. — 2019
• I-Mab Biopharma / Shanghai Junshi Biosciences Co., Ltd. — 2019
• Janssen Pharmaceuticals, Inc. / MeiraGTx Holdings plc — 2019
• Sarepta Therapeutics Inc. / Myonexus Therapeutics — 2019
• Alfasigma S.p.A. / Innovation Pharmaceuticals — 2019
• Pfizer Inc. / Vivet Therapeutics S.A.S. — 2019 · $635M
• Aquinox Pharmaceuticals, Inc. / Neoleukin Therapeutics, Inc. — 2019
• Hanmi Pharmaceutical Co. Ltd. / RAPT Therapeutics, Inc. — 2019
• Takeda Pharmaceutical Company Limited / StrideBio, Inc — 2019
• Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. — 2019 · $1.2B
• Eurofarma / NLS-1 Pharma — 2019
• Merck & Co. Inc. / Bioncotech Therapeutics — 2019
• Kiadis Pharma NV / CytoSen Therapeutics, Inc. — 2019
• BeiGene Ltd. / Ambrx Inc. — 2019
• Roche Holding AG / Xencor, Inc. — 2019 · $1.6B
• NJCTTQ (Nanjing CTTQ Pharma) / Abpro Corporation — 2019 · $4.0B
• Daiichi Sankyo Company, Limited / ProLynx LLC — 2019
• Roche Holding AG / Skyhawk Therapeutics Inc. — 2019 · $2.0B
• AbbVie / Idera Pharmaceuticals, Inc. — 2019
• Terns Pharmaceuticals / GENFIT — 2019
• SQZ Biotechnologies / Asklepios BioPharmaceutical, Inc. — 2019
• AbbVie / Tizona Therapeutics, Inc. — 2019
• Cara Therapeutics, Inc. / Enteris Biopharma, Inc. — 2019
• Newsoara BioPharma Co., Ltd. / Zenith Epigenetics Ltd. — 2019
• Grifols S.A. / Rigel Pharmaceuticals, Inc. — 2019
• Mitsubishi Tanabe Pharma Corporation / Viela Bio Inc. — 2019
• Shionogi & Co., Ltd. / Hsiri Therapeutics, Inc. — 2019
• Alkermes plc / Rodin Therapeutics, Inc. — 2019 · $950M
• Jazz Pharmaceuticals plc / Codiak BioSciences, Inc. — 2019
• Bristol-Myers Squibb Company / Mirati Therapeutics, Inc. — 2019
• Alkermes plc / Clovis Oncology, Inc. — 2019
• SWK Holdings Corporation / Enteris Biopharma, Inc. — 2019
• Specialised Therapeutics Asia / Onconova Therapeutics, Inc. — 2019
• Ono Pharmaceutical Co., Ltd. / Rafael Pharmaceuticals, Inc. — 2019
• Bayer AG / KaNDy Therapeutics Ltd. — 2019 · $875M
• Pfizer Inc. / Therachon Holding AG — 2019 · $810M
• Eli Lilly and Company / Centrexion Therapeutics Corporation — 2019 · $575M
• Screen Therapeutics LLC / Immunaccel — 2019
• AbbVie Inc. / Harpoon Therapeutics — 2019 · $510M
• Bayer AG / BlueRock Therapeutics LP — 2019 · $600M
• Chipscreen Biosciences Co., Ltd. / Novogene Co., Ltd. — 2019
• Alexion Pharmaceuticals Inc. / Achillion Pharmaceuticals, Inc. — 2019 · $1.2B
• Acer Therapeutics Inc. / Sanofi — 2019
• Boehringer Ingelheim GmbH / Yuhan Corporation — 2019 · $870M
• Petra Pharma Corporation / Takeda Pharmaceutical Company Limited — 2019
• Denovo Biopharma LLC / Sunesis Pharmaceuticals — 2019
• Sobi (Swedish Orphan Biovitrum AB) / Dova Pharmaceuticals, Inc. — 2019 · $915M
• Theratechnologies Inc. / Katana Biopharma Inc. — 2019
• C4X Discovery Holdings plc / PhoreMost — 2019
• Phio Pharmaceuticals Corp. / Carisma Therapeutics — 2019
• Incyte / BriaCell Therapeutics Corp. — 2019
• Knight Therapeutics Inc. / Triumvira Immunologics Inc. — 2019
• Asklepios BioPharmaceutical, Inc. / Selecta Biosciences, Inc. — 2019
• Zambon S.p.A. / Aquestive Therapeutics, Inc. — 2019
• Catalent, Inc. / Paragon Bioservices, Inc. — 2019 · $1.2B
• AbbVie Inc. / Boehringer Ingelheim GmbH (Risankizumab buyout) — 2019 · $595M
• Eli Lilly and Company / ImmuNext Inc. (anti-VISTA license) — 2019 · $350M
• Roche Holding AG / Promedior, Inc. — 2019 · $1.4B
• Altimmune, Inc. / Spitfire Pharma, Inc. — 2019
• Merck KGaA, Darmstadt, Germany / Y-Trap, Inc. — 2019

← Deal Library  ·  Interactive search  ·  How we score deals